• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
april@madhedgefundtrader.com

November 20, 2024

Jacque's Post

 

(TRUMP’S GAME OF CHESS WITH RUSSIA)

 

November 20, 2024

 

Hello everyone

 

Trump, the dealmaker, will have to use all his “box of tricks” and then some to secure an end to the conflict between Ukraine & Russia.

 

 

Let’s remember it was Trump’s boast that he would end the war in a day.  We’re not there yet.

One thing is certain, and that is that President Zelensky will come under heavy pressure from the newly elected Trump administration to reach a settlement with Moscow. 

But what if Zelensky feels backed into a corner?  What will be his reaction? 

For those of us who live far away from the conflict zone, we may think that the impact of this war will be minimal on our life.  But, the outcome of the Ukraine conflict will have global consequences.  Even Australia won’t be immune. 

Let’s sit with this idea for a moment.  A Putin win will encourage his expansionist impulses in Asia, as well as Europe, strengthen the axis of autocrats, devitalize the democracies, and promote a deals-based order where the strong do what they will, and the rest of us roll with the fall-out as best we can.

How Trump, the dealmaker, behaves and acts regarding this conflict will be telling, as his actions will illustrate America’s international policy in a Trump-revived world.

It is probable that Trump’s actions will be more robust than Biden’s.  Biden provided enough weaponry to continue the war but not enough for the Ukrainians to fully exploit Russia’s weaknesses and gain the upper hand. 

Biden’s 11th-hour concession allowing Ukraine to strike Russia with long-range US missiles may be too little, too late.

So, what does Trump’s peace plan look like?

Kyiv will likely have to give up territory in exchange for US security assurances and European financial support for post-war reconstruction.  The current battle lines could become a border – a heavily fortified 1200km long demilitarised zone patrolled by a multinational peacekeeping force.

So, now Putin would be in control of 20 percent of Ukraine. 

What a heavy price to pay for that territory!

600,000 Russian soldiers were killed.

And economically, the war has been a debacle.

Russia’s strategic position has been weakened by the self-inflicted enlargement of NATO to include Sweden and Finland along its northwestern border.

Without US military support, it is hard to see Ukraine winning this war with Russia. Zelensky may find himself in a position where he must accept Trump’s plan since Europe is not willing or even able to fill the gap.    The EU couldn’t even provide the million 155mm artillery shells promised to Ukraine by March.

Getting Putin to agree might prove tricky for Trump.

Complicating the negotiations is the fact that North Korea’s “Storm Corps” are fighting on Russia’s side.  Now, we can see how this conflict seems to be gradually changing into a Eurasia-wide struggle for geopolitical ascendancy.

In this war, North Koreans serve a good tactical and political purpose for Putin.  They won’t change the course of the war.  But their involvement may deepen a sense of isolation Ukrainians feel as the axis forces work together to crush their resistance.  Europe’s support is softening, and under Trump, Americans are poised to bail out.

A bilateral defence pact signed in June between Russia and North Korea will see the hermit kingdom benefitting nicely. 

$200m for its troops and the provision of missile and satellite technology, as well as

700,000 tonnes of rice to feed the half-starved population.

Should South Korea begin arming Ukraine, this could destabilize the relationship with North Korea and easily ignite an Asia-wide conflict.  This would draw Australia into the war, as we have a historical commitment to the defense of South Korea.

How this plays out – nobody really knows. 

It has become a game of chess.

But one thing has become clear – democracies will need to grow a backbone, show some brawn, and match the defense spending and singlemindedness of the autocrats.  They play to win at all costs.  We need to up the ante and check them before they check mate us.

 

 

 

PORTFOLIO REVIEW

I would think about taking some profits from your gold stocks.  Most of you will be sitting on healthy profits – take some off the table.

(GDX), (AGQ), (WPM), (GOLD), (SLV)

QI CORNER

 

 

SOMETHING TO THINK ABOUT

 

 

 

 

Cheers

Jacquie

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-20 12:00:292024-11-20 13:16:55November 20, 2024
april@madhedgefundtrader.com

November 20, 2024

Diary, Newsletter, Summary

Global Market Comments
November 20, 2024
Fiat Lux

 

Featured Trade:

(THE JOHN THOMAS BIOGRAPHY IS OUT)
(THE EIGHT WORST TRADES IN HISTORY)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-20 09:06:292024-11-20 10:32:52November 20, 2024
april@madhedgefundtrader.com

November 19, 2024

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
November 19, 2024
Fiat Lux

 

Featured Trade:

(HONEY, I SHRUNK THE MARKET CAP)

(ABBV), (BMY), (AVNX)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-19 12:02:072024-11-19 12:22:39November 19, 2024
april@madhedgefundtrader.com

Honey, I Shrunk The Market Cap

Biotech Letter

If you've ever wondered what $9 billion in disappointment looks like, ask the folks at AbbVie (ABBV). They've just learned the hard way that even the most promising psychiatric drugs can pull a vanishing act worthy of Houdini when it comes to clinical trials.

Their great hope, emraclidine – a name that sounds like it could either cure schizophrenia or clean your bathtub – recently face-planted in not one, but two Phase 2 trials.

Dr. Roopal Thakkar, AbbVie's Chief Scientific Officer, probably wishes this particular day came with a reset button, as the company's experimental once-daily pill performed with all the therapeutic punch of a sugar tablet in treating schizophrenia.

Somewhere, in a parallel universe, there's probably a version of Dr. Thakkar who didn't just watch $40 billion in market value evaporate faster than a teenager's allowance at a gaming convention.

Unfortunately, in our universe, AbbVie's stock took a 12.6% nosedive to $174.43.

But here's where it gets interesting, in that peculiar way that only Wall Street can manage. While AbbVie was having its very bad, no-good day, Bristol Myers Squibb (BMY) was practically dancing in the streets.

Their shares shot up 11% faster than you can say "competitive advantage." Why? Because their own schizophrenia drug, Cobenfy (another name that sounds like it came from the same random pharmaceutical name generator), just got the FDA's blessing.

Talk about impeccable timing.

Let's put this in perspective: We're talking about a global market worth $7.90 billion in 2023, projected to balloon to $11.35 billion by 2030. And it's not just about money.

The World Health Organization tells us there are 24 million people worldwide living with schizophrenia.

In the U.S. alone, it affects between 0.25% and 0.64% of adults, according to the National Institute of Mental Health. That's roughly the population of a small city, all waiting for better treatment options.

Meanwhile, other players in this high-stakes game are making moves that would impress a chess grandmaster.

Take Teva Pharmaceutical Industries (TEVA), busy cooking up a long-acting injectable version of olanzapine.

Or Alkermes plc (ALKS), sitting pretty with their $1.17 billion in revenue for 2022, thanks partly to their own injectable antipsychotic, Aristada.

Then there's H. Lundbeck A/S (HLBBF), the Danish company that spends 18% of its $2.7 billion revenue on R&D, like a scientist with an unlimited coffee budget.

And let's not forget the plucky underdog, Anavex Life Sciences Corp. (AVXL), burning through cash like a marathon runner through calories ($31.6 million in losses for 2022) while chasing their own psychiatric breakthrough.

Their compound, ANAVEX 3-71, sounds like a droid from Star Wars but might just be the next big thing in schizophrenia treatment. Or not.

That's the beauty and terror of biotech investing – you never quite know if you're backing the next breakthrough or the next spectacular failure.

AbbVie, thankfully, isn't exactly heading for the poorhouse. Their blockbuster drug Humira raked in $21 billion in 2022 alone – enough to buy everyone in New Zealand a really nice dinner.

The truth is, navigating the biotech market is less like following a recipe and more like trying to predict where lightning will strike while riding a unicycle.

So here's your biotech shopping list, served with a side of market reality.

AbbVie's spectacular face-plant has created a buying opportunity for the patient investor (that $21 billion Humira cushion makes for a soft landing).

Bristol Myers Squibb is strutting around with their fresh FDA approval like they own the place (and right now, they kind of do).

And if you're feeling particularly adventurous, Anavex Life Sciences offers a lottery ticket that might just pay off.

Whatever you choose, just remember to keep your antacids handy.

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-19 12:00:082024-11-19 12:22:25Honey, I Shrunk The Market Cap
april@madhedgefundtrader.com

Trade Alert - (VST) November 19, 2024 - BUY

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-19 11:11:592024-11-19 11:11:59Trade Alert - (VST) November 19, 2024 - BUY
april@madhedgefundtrader.com

Trade Alert - (CCJ) November 19, 2024 - TAKE PROFITS - SELL

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-19 10:35:352024-11-19 10:35:35Trade Alert - (CCJ) November 19, 2024 - TAKE PROFITS - SELL
april@madhedgefundtrader.com

November 19, 2024

Diary, Newsletter, Summary

Global Market Comments
November 19, 2024
Fiat Lux

 

Featured Trade:

(JANUARY 10 MIAMI FLORIDA STRATEGY LUNCHEON)
(THE MAD HEDGE DICTIONARY OF TRADING SLANG),
(TESTIMONIAL)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-19 09:08:412024-11-19 11:54:51November 19, 2024
MHFTR

Testimonial

Diary, Newsletter

I am basically writing this email to thank you so much for coming to Australia.

Thank you again for sparing the time, for being present to hear our questions, for sharing your valued insights and knowledge and in addition to all that thank, you for your friendship.

As I said on the occasion, I was hoping for a sunny occasion for your visit to Café Sydney knowing that you would only be here for one day.

It was delightful to have the Sydney Harbour Bridge, the harbour and the Opera House bathed in pleasant autumn sun for your time with us.

As a postscript, I have an ongoing interest in the military combat in the Pacific of World War II and I have often visited on the net the stories of the combat at Guadalcanal, Tarawa, Palau, Iwo Jima, and Okinawa.

I was therefore quite electrified by your May 29 Diary of a Mad Hedge Fund Trader. You truly have an awesome family history indeed!

I rechecked the story on the battle for Henderson field and sure enough, within it is a section on Oka’s attack and the opposition he faced from a company machine gun section under Mitchel Paige

Interesting to learn of his Serbian origin - not Paige but Pejic. On your website, the first article about the next Korean War has a photo of you when you were younger from which I see a great resemblance to your uncle!

Many Thanks!
Ian
Sydney, Australia

 

https://www.madhedgefundtrader.com/wp-content/uploads/2018/10/John-Thomas-Sydney.png 345 377 MHFTR https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png MHFTR2024-11-19 09:02:332024-11-19 11:53:30Testimonial
Douglas Davenport

LESS IS MOORE

Mad Hedge AI

(NVDA), (AMZN), (GOOG), (MSFT), (AMD), (TSM)

If Moore's Law had a therapist, today's session would be about AI. "Doctor, I can't keep up with their demands!" it would say. "These AI models are getting needier than my ex." 

After riding every tech wave since CPUs ran at 8MHz, I recognize this moment: the AI industry is hitting what physicists call a phase transition - that point when adding more heat doesn't make water any hotter, it just turns it into steam. 

And steam, my friends, is exactly what we're seeing come out of some AI companies' valuations.

For years, AI companies played a simple game - throw more computing power at the problem, add more data, watch the magic happen. It worked beautifully, until it didn't. 

Think of it this way: OpenAI's GPT-4, released over two years ago, is like that trader who peaked early - still impressive, but newer models with bigger budgets aren't managing to beat its performance.

But markets, like nature, abhor a vacuum. While everyone was obsessing over model size, something more interesting emerged: test-time compute. 

Instead of training ever-larger models upfront (think of it as cramming for an exam), test-time compute lets AI systems reason through problems step-by-step in real-time (more like thinking through questions during the test). 

OpenAI's experimental "o1" model proved this brilliantly: given 20 seconds to analyze a poker game, it matched the performance of models 100,000 times its size. This isn't just an incremental improvement - it's a fundamental shift in how AI processes information, similar to how high-frequency trading revolutionized market making.

Now, let's talk about where the smart money is flowing. The hardware market is about to go through the kind of transformation I witnessed in the early days of the internet boom. 

Remember when everyone thought AOL would dominate the internet forever? That's the kind of assumption we need to challenge here.

NVIDIA, with a market cap $3.48 trillion, has been the undisputed champion of AI chips, with data center revenue soaring 171% to $10.32 billion in 2023. But just as I learned in my early days of trading, market dominance can be a temporary condition. 

AMD, with a market of $282 billion, is making serious moves in the inference hardware space, with their stock up 75% in 2023. Their lower valuation and strategic focus on inference chips positions them perfectly for the test-time compute revolution. 

Meanwhile, Taiwan Semiconductor Manufacturing’s (TSM) 43% revenue increase isn't just a number - it's a signal. With a P/E of 22 and their commanding lead in advanced chip manufacturing, they're the picks-and-shovels play in this new gold rush.

Next, let’s take a look at the cloud providers - Amazon (AMZN), Microsoft (MSFT), and Google (GOOG) - which hold a unique position here. 

Amazon's AWS division raked in $23.1 billion in operating income, while Microsoft's Azure revenue jumped 29% in 2023 through their OpenAI partnership. 

Alphabet's DeepMind might look like a money pit to traditional analysts - their "Other Bets" category pulled in $1.29 billion in 2023 - but they're actually rethinking how AI computes.

Aside from these big names, a handful of up and coming companies are making waves as well. 

One of them is Cerebras Systems, the current leader in specialized AI hardware with their wafer-scale engine - essentially an entire datacenter on a chip. 

While still private, they're showing how radical innovation in hardware architecture can leapfrog traditional approaches. 

We're seeing a shift from massive training clusters to what I call "thinking infrastructure" - distributed systems optimized for real-time processing.

Looking at the broader market, we're entering what I consider a sorting period. 

The companies that understand this shift away from scale will thrive. Those still playing the old game of bigger-is-better will struggle. 

So, what’s the play? I say buy the dip for AMD since their focus on inference chips and reasonable valuation makes them perfectly positioned for the test-time compute revolution. 

Do the same for TSM. Their manufacturing prowess and diverse customer base provide both stability and upside in this transition.

Meanwhile, press pause on NVIDIA for now. Despite their premium valuation, their technical leadership and massive installed base warrant holding positions. Still, be on the lookout for signs of adaptation to the new rules. 

Most importantly, set tight stops - this transition period will be volatile. I'm looking at a 6-12 month horizon here, with position reviews every 30 days.

https://www.madhedgefundtrader.com/wp-content/uploads/2024/11/Screenshot-2024-11-18-154829.png 738 739 Douglas Davenport https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Douglas Davenport2024-11-18 15:49:342024-11-18 15:50:40LESS IS MOORE
april@madhedgefundtrader.com

November 18, 2024

Tech Letter

Mad Hedge Technology Letter
November 18, 2024
Fiat Lux

 

Featured Trade:

(SPOTIFY WORTH A LOOK)
(SPOT), (META), (PINS)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-18 14:04:022024-11-18 15:48:23November 18, 2024
Page 5 of 14«‹34567›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
Scroll to top